Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

First-Line ER-Positive MBC Treatments

August 5th 2014

Changing Treatment Landscape in Metastatic Breast Cancer

August 5th 2014

Novel EGFR Specific Agents Impress in NSCLC

August 2nd 2014

Third generation EGFR TKIs have demonstrated dramatic benefits for patients with non-small cell lung cancer (NSCLC) and should be considered as a standard second-line option following resistance to frontline therapy

Dr. Hirsch Discusses the Role of Next-Generation EGFR Inhibitors

August 1st 2014

Fred R. Hirsch, MD, PhD Professor of Medicine and Pathology, Associate Director for International Programs, University of Colorado Cancer Center, discusses the role of next-generation EGFR inhibitors.

Glycans Emerge as Promising Biomarkers for Early Detection of Many Cancer Types

July 30th 2014

For many years, we in the medical and research communities have tried to use proteins and DNA fragments as disease markers to find cancer early.

Promising Findings for Afatinib-Cetuximab Combo in Previously Treated EGFR-Mutant Lung Cancer